Financial reports
Current reports
6-K
Addex Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update
18 Apr 24
6-K
Addex and Perceptive Launch Neurosterix with $63 Million to Accelerate Development of Allosteric Modulator Therapeutics for Neurological Disorders
3 Apr 24
6-K
Current report (foreign)
30 Jan 24
6-K/A
Current report (foreign) (amended)
21 Dec 23
6-K
Addex Shareholders Approve All Resolutions at Extraordinary General Meeting
20 Dec 23
6-K
Addex Creates Treasury Shares
14 Dec 23
6-K
Current report (foreign)
29 Nov 23
6-K
Addex Convenes Extraordinary General Meeting
28 Nov 23
6-K
Addex ADX71149 Epilepsy Phase 2 Study Completes Recruitment of Patients
14 Nov 23
6-K
Current report (foreign)
8 Nov 23
Registration and prospectus
424B3
Prospectus supplement
24 Apr 24
POS AM
Prospectus update (post-effective amendment)
18 Apr 24
424B5
Prospectus supplement for primary offering
30 Jan 24
424B3
Prospectus supplement
30 Nov 23
POS AM
Prospectus update (post-effective amendment)
29 Nov 23
424B3
Prospectus supplement
23 Oct 23
F-6 POS
Automatic registration for ADRs (post-effective amendment, foreign)
6 Oct 23
424B3
Prospectus supplement
11 Aug 23
POS AM
Prospectus update (post-effective amendment)
10 Aug 23
S-8
Registration of securities for employees
8 Jun 23
Proxies
No filings
Other
EFFECT
Notice of effectiveness
23 Apr 24
EFFECT
Notice of effectiveness
30 Nov 23
EFFECT
Notice of effectiveness
11 Aug 23
EFFECT
Notice of effectiveness
5 Jun 23
CORRESP
Correspondence with SEC
1 Jun 23
CORRESP
Correspondence with SEC
12 May 23
CORRESP
Correspondence with SEC
11 May 23
UPLOAD
Letter from SEC
9 May 23
EFFECT
Notice of effectiveness
30 Aug 22
EFFECT
Notice of effectiveness
30 Aug 22
Ownership
SC 13D/A
Growth Equity Opportunities Fund IV, LLC
8 Dec 23
SC 13D/A
Dyer Timothy Mark
29 Nov 23
SC 13D/A
Growth Equity Opportunities Fund IV, LLC
10 Apr 23
SC 13D/A
Dyer Timothy Mark
5 Apr 23
SC 13D/A
Dyer Timothy Mark
31 Mar 23
SC 13G/A
ARMISTICE CAPITAL, LLC
16 Feb 23
SC 13G/A
CAXTON CORP
14 Feb 23
SC 13G/A
ARMISTICE CAPITAL, LLC
14 Feb 23
SC 13G/A
GOLDMAN SACHS GROUP INC
8 Feb 23
SC 13G/A
New Leaf Biopharma Opportunities I, L.P.
6 Feb 23